Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
SURMOUNT-5, published in the New England Journal of Medicine in 2025, directly compared tirzepatide to semaglutide
The FDA shortage designation for semaglutide and tirzepatide has been resolved, and the FDA has proposed excluding these drugs from the 503B bulks list
In Springfield, Missouri, patients observe significant enhancements in metabolic health indicators, including more balanced blood sugar levels, decreased blood pressure, and better cholesterol profiles
In addition, rates of non-fatal heart attacks, non-fatal strokes, and hospitalizations for heart failure were all lower among patients using the drugs
US$ 27.23
US$ 28.30
US$ 29.71
US$ 20.35
US$ 28.59
